Home | Welcome to Contract Pharma   
Last Updated Tuesday, September 30 2014
Print

Financial Report: BASi



Published August 14, 2014
BASi

3Q Revenues: $6.0 million (+8%)

3Q Earnings: $215,000 (-63%)

YTD Revenues: $18.2 million (+10%)

YTD Loss: $666,000 (earnings were $521 million YTD13)

Comments: Service revenue in the quarter increased 14% to $4.8 million primarily due to higher toxicology revenue, offset slightly by lower bioanalytical analysis revenue. Product revenue decreased 12% to $1.3 million. Earnings in the quarter and YTD were affected by non-cash decreases in the fair value of warrant liability of $66,000 and $1.1 million, respectively.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On